Guide to Leading a Patient with Symptoms of an Acute Respiratory Infection during a Coronavirus Pandemic (COVID-19)

  • Velo Markovski Faculty of Medical Sciences, University of Goce Delchev, Shtip, Republic of Macedonia
Keywords: COVID-19, Primary viral pneumonia, Severe pneumonia, Typical pneumonia, Secondary mycotic pneumonia, Therapy

Abstract

BACKGROUND: Over 500 viruses and bacteria primarily cause respiratory infections. During COVID-19 pandemic, these respiratory infections remain; i.e., COVID-19 has no ability to suppress these infections from the circulation. Therefore, it is very important to differentiate respiratory infections from COVID-19. Proving the presence of COVID-19 with polymerase chain reaction (PCR) is not evidence that the disease was caused by this virus. Possible options are: First, a random encounter of the virus in the patient’s upper respiratory tract; second, further possible colonization with a coronavirus (or with COVID-19); the third option is to have an infection; and the fourth possibility is to have a disease or COVID-19 upper respiratory infection. Unfortunately, the method with PCR, although it is with high sensitivity and specificity, does not help us to distinguish which of these four possibilities are in question.

AIM: We aimed to present a guide to leading a patient with symptoms of an acute respiratory infection during a coronavirus pandemic (COVID-19).

RESULTS: A pandemic of COVID-19 shows that many patients get primary viral pneumonia, but people with normal immune system have no problem recovering. People with reduced immunity die from COVID-19, as opposed to the pandemic influenza virus. It is indirectly concluded that COVID-19 in itself is not very virulent, but it weakens the immunity of those infected who already have some condition and impaired immunity. The available scientific papers show that there is no strong cytokine response, patients have leukopenia and lymphopenia, some patients have a decrease in CD4 T-lymphocytes. From the results of the autopsies available so far, it is clear that there are very few inflammatory cells in the lungs and a lot of fluid domination. Hence, SARS-Cov-2 only somehow speeds up the decline in immunity. The previously published radiographic findings of COVID-19 patients, gave a characteristic findings of the presence of multifocal nodules, described as milky glass, very often localized in the periphery of the lung. Whether it is typical pneumonia, atypical, viral, mixed-type pneumonia, or mycotic pneumonia, it can progress to severe pneumonia. The pneumonia becomes severe when breathing is over 30/min; diastolic pressure below 60 mmHg; low partial oxygen pressure in the blood (PaO2/FiO2 <250 mmHg) (1 mmHg = 0.133 kPa); massive pneumonia, bilateral or multilayered lung X-ray; desorientation; leukopenia; and increased urea.

CONCLUSION: Patients with COVID-19 placed in intensive care units should be led by a team of anesthesiologists with an infectious disease specialist or an anesthesiologist with a pulmonologist. Critical respiratory parameters should be peripheral oxygen saturation <90%, PaO2/FiO2 ratio 100 or <100, tachycardia above 110/min.

 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett’s principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010. p. 218. https://doi.org/10.1086/655696

Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. https://doi.org/10.3390/ v12020135

Daltro P, Santos EN, Gasparetto TD, Ucar ME, Marchiori E. Pulmonary infections. Pediatr Radiol. 2011;41 Suppl 1:S69-82. https://doi.org/10.1007/s00247-011-2012-8

Alosaimi B, Hamed ME, Naeem A, Alsharef AA, AlQahtani SY, AlDosari KM, et al. MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/ chemokines and elevated inflammatory innate immune response in the lower respiratory tract. Cytokine. 2020;126:154895. https://doi.org/10.1016/j.cyto.2019.154895 PMid:31706200

Aiba H, Mochizuki M, Kimura M, Hojo H. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology. 2001;57(2):295-9. https://doi. org/10.1212/wnl.57.2.295 PMid:11468315

Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153(6):725-33. https://doi.org/10.1093/ajcp/aqaa062

Benedict K, Park BJ. Invasive fungal infections after natural disasters. Emerg Infect Dis. 2014;20(3):349-55. https://doi. org/10.3201/eid2003.131230 PMid:24565446

Markovski V. Influenza: Epidemics and Pandemics. LAP Lambert Academic Publishing, 2013.

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis. 2020;20(4):425- 34. https://doi.org/10.1016/s1473-3099(20)30086-4 PMid:32105637

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):P1054-62. https://doi.org/10.1016/ s0140-6736(20)30566-3

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. https://doi.org/10.1016/s0140-6736(20)30628-0

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239-42. https://doi.org/10.1001/jama.2020.2648 PMid:32091533

Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ. 2020;368:m792. https://doi. org/10.1136/bmj.m606 PMid:32107200

Kuzman I, Bezlepko A, Topuzovska IK, Rókusz L, Iudina L, Marschall HP, et al. Efficacy and safety of moxifloxacin in community acquired pneumonia: A prospective, multicenter, observational study (CAPRIVI). BMC Pulm Med. 2014;14(1):105. https://doi.org/10.1186/1471-2466-14-105 PMid:24975809

Aiba H, Mochizuki M, Kimura M, Hojo H. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology. 2001;57(2):295-9. https://doi. org/10.1212/wnl.57.2.295 PMid:11468315

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;2020:ciaa248. https://doi.org/10.1093/cid/ ciaa248 PMid:32161940

Zheng Y, Huang Z, Yin G, Zhang X, Ye W, Hu Z, et al. Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. Lancet. 2020. https://doi.org/10.2139/ssrn.3555267

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: The perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-4. https://doi.org/10.1038/ s41418-020-0530-3 PMid:32205856

Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: Diagnosis and clinical management. Indian J Med Res. 2014;139(2):195. PMid:24718393

Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020;2020:11. https://doi.org/10.1001/ jama.2020.3633 PMid:32159735

Published
2020-06-30
How to Cite
1.
Markovski V. Guide to Leading a Patient with Symptoms of an Acute Respiratory Infection during a Coronavirus Pandemic (COVID-19). Open Access Maced J Med Sci [Internet]. 2020Jun.30 [cited 2020Sep.20];8(T1):97-102. Available from: https://www.id-press.eu/mjms/article/view/4848